



HEMATOLOGY

PEER GROUP REPORT

HORIBA INSTRUMENTS- H550/H1500

Cycle-13/2024

Round -05 Lab Code: 3351 Date: 28/10/2024

Complete Blood Count (CBC)

| Parameters | Instrument Group | No. of Participants | Robust Mean | Robust Standard deviation (SD) | Uncertainty of Assign Values | Range (± 2 SD) | Your Value | Z Score |
|-----------------------------------|-----------------------|------------------------|----------------|---|------------------------------------|-------------------|---------------|---------|
| Hb gm/dl | Horiba- H550/H1500 | 62 | 11.9 | 0.5 | 0.08 | 10.9-12.9 | 11.0 | -1.8 |
| WBC \times 10 3 / μ l. | Horiba- H550/H1500 | 62 | 8.3 | 0.6 | 0.10 | 7.1-9.6 | 8.3 | 0.0 |
| RBC \times 10 6 / μ l. | Horiba- H550/H1500 | 62 | 4.2 | 0.2 | 0.03 | 3.8-4.7 | 3.85 | -1.8 |
| Hct% | Horiba- H550/H1500 | 62 | 35.8 | 1.9 | 0.30 | 32.0-39.6 | 33.9 | -1.0 |
| MCV fl. | Horiba- H550/H1500 | 62 | 84.5 | 2.1 | 0.33 | 80.2-88.8 | 88.2 | 1.8 |
| MCH pg. | Horiba- H550/H1500 | 62 | 28.1 | 0.6 | 0.10 | 26.9-29.3 | 28.5 | 0.7 |
| MCHC gm/dl | Horiba- H550/H1500 | 62 | 33.0 | 0.8 | 0.13 | 31.4-34.7 | 32.3 | -0.9 |
| Platelet × 10³/μl. | Horiba- H550/H1500 | 62 | 351.5 | 19.5 | 3.10 | 312.4-390.6 | 342 | -0.5 |

Interpretation of Z Score:

| Z Score Value(+/-) | [Z] ≤ 2.0 | 2.0< [Z] < 3.0 | [z] ≥ 3.0 |
|--------------------|--|--------------------------------|--|
| Interpretation | Satisfactory Performance No signal | Questionable Warning Signal | Unsatisfactory Performance action Signal |

Chief Coordinator

Programme Director

Dr. Sanjay Mehrotra

Dr.Bandana Mehrotra

Prepared By: TC

Checked By: 9=

End of Report





Doc. No.: ASS / FR / 06H / R 01 / Dt.: 20.02.2024





RML-Quality Assurance Program (RML-QAP)



Differential Leukocyte Count

(Digital Hematology QAP)

Digital Hematology Morphology QAP Programme

Participant Result of Round-05, Cycle-13

Lab Code: 3351

- **1.** One slide was sent for Digital Hematology Morphology for Round -05, C-13.
- **2.** For Round-05, C-13, the total number of participants enrolled in the Digital Hematology Morphology Program was 493.
- **3.** For slide 01, there were 270 responses were received.
- **4.** Individual participant's results are available on their respective login site on the web. The details of the morphological agreement and disagreement with pictures are also available on the portal for review.
- 5. The Expert comments for the Submitted slides were examined by three experienced examiners at RML-QAP.
- 6. The Slides submitted were stained by Wright-Giemsa stains.
- **7.** The Examiner Details of RML- QAP Digital Hematology Morphology R-05, C-13 slides:

Slide 01: Expert opinion -- Acute Leukemia -ALL

- 8. The ICSH guidelines for morphological assessment recommend standardizing nomenclature and grading peripheral blood cell morphological features.
- **9.** Gulati's reference, which was shared in the last email, is recommended for RBC morphology evaluation and grading.

Doc. No.: ASS / FR / 06 J / R 01 / Dt.: 05.01.2024







RML-Quality Assurance Program (RML-QAP)



Differential Leukocyte Count

(Digital Hematology QAP)

Digital Hematology Morphology QAP Programme

Participant Result of Round-05, Cycle-13

Lab Code: 3351 Slide-01

- 270 participants participated in slide -01.
- Result of the RML-QAP examiners largely agreed with the group majority.
- Compared to the **examiner**, the average WBC agreement was **75.9** %.
- Compared to the **examiner**, the average RBC agreement was **85.7 %**.
- Compared to the majority of participants, the average WBC agreement was 74.1 %.
- Compared to the majority of participants, the average RBC agreement was 100.0 %.

Compared to Examiner

WBC RBC Agreement 75.9 % 85.7 %

Compared to the Majority of Participants

| WBC | RBC | | |
|-----------|-----------|--|--|
| Agreement | Agreement | | |
| 74.1 % | 100.0 % | | |

Your Slide 1 Comment: NIL

Criteria for Evaluation

| % of Agreement | Performance |
|----------------|------------------|
| <50 | Poor performance |
| 50-60 % | Borderline |
| 60-70 % | Satisfactory |
| 70-80 % | Good |
| >80 % | Optimal |

<mark>End of Report</mark>

Chief Coordinator

Programme Director

Dr. Sanjay Mehrotra

Dr. Bandana Mehrotra

Prepared By: SM

Checked By:

Doc. No.: ASS / FR / 06 J / R 01 / Dt.: 05.01.2024



